BriaCell Therapeutics Corp. Common Shares (BCTX)
BCTX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BCTX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Canada |
| IPO year | Not reported by the screener |
| SEC CIK | 0001610820 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | BC |
| Canadian listing | TSX: BCT |
Financials
Foreign filer: no machine-readable annual figure in SEC data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As discussed in Note 1 to the consolidated financial statements, the Company incurred operating losses, negative cash flows from operating activities and has an accumulated deficit that raise substantial doubt about its ability to continue as a going concern." | 10-K 2026-10-28 |
| Cash and burn | $9.9M cash; operating cash flow -$7.2M a quarter. | Report 2026-07-31 |
| Shares outstanding | 8,732,381 (2026-10-28); 1,883,906 a year earlier; 15,981,726 three years earlier. 3y figure adjusted for splits (1-for-10 overall). | Cover page 2026-10-28 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2025-08-25 | Source 2025-08-25 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-06-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Delisting | 25-NSE filed | 25-NSE 2026-02-26 |
| Auditor | MNP LLP, Toronto, Canada | PCAOB Form AP 2026-10-29 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q4 2026 2026-07-31 | Not filed | -$12.3M | -$6.0M | $9.9M | No debt tags | Needs four quarters | 10-K 2026-10-28 |
| Q3 2026 2026-04-30 | Not filed | -$7.2M | -$7.0M | $6.9M | No debt tags | Needs four quarters | 10-Q 2026-06-09 |
| Q2 2026 2026-01-31 | Not filed | -$7.2M | -$8.0M | $29.9M | No debt tags | Needs four quarters | 10-Q 2026-03-10 |
| Q1 2026 2025-10-31 | Not filed | -$8.2M | -$7.7M | $2.7M | No debt tags | Needs four quarters | 10-Q 2025-12-11 |
| Q4 2025 2025-07-31 | Not filed | -$8.1M | -$8.1M | $10.5M | No debt tags | Needs four quarters | 10-K 2026-10-28 |
| Q3 2025 2025-04-30 | Not filed | -$6.1M | -$7.2M | $12.5M | No debt tags | Needs four quarters | 10-Q 2026-06-09 |
| Q2 2025 2025-01-31 | Not filed | -$6.3M | -$5.9M | $5.0M | No debt tags | Needs four quarters | 10-Q 2026-03-10 |
| Q1 2025 2024-10-31 | Not filed | -$5.8M | -$7.0M | $5.8M | No debt tags | Needs four quarters | 10-Q 2025-12-11 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-06-02 |
| Latest annual report | 10-K | 2026-10-28 |
| Latest quarterly / interim | 10-Q | 2026-06-09 |
| Latest current report | 8-K | 2026-06-26 |
| Latest proxy | DEF 14A | 2026-02-12 |
Source: SEC EDGAR submissions feed, 324 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -14.2% |
| 1 month | -8.6% |
| 3 months | -1.5% |
| Year to date | -52.3% |
| 1 year | -65.2% |
| From 52-week high | -73.2% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Other listings for this company
| Ticker | Name | Price |
|---|---|---|
| BCTXL | BriaCell Therapeutics Corp. Warrant expiring 2031 | $0.8200 |
| BCTXZ | BriaCell Therapeutics Corp. Warrant expiring 2030 | $0.1149 |
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| SCYX | SCYNEXIS Inc. | $2.91 | -9.35% | $29.0M |
| PMN | ProMIS Neurosciences Inc. Common Shares (ON) | $3.31 | +0.61% | $29.8M |
| AARD | Aardvark Therapeutics Inc. | $1.26 | -5.26% | $27.6M |
| NXTC | NextCure Inc. | $6.68 | +4.38% | $30.6M |
| RMTI | Rockwell Medical Inc. | $6.76 | -4.38% | $26.9M |
| NSRX | Nasus Pharma Ltd. | $2.66 | -7.32% | $31.2M |
| MIRA | MIRA Pharmaceuticals Inc. | $0.6310 | -4.38% | $26.5M |
| NNVC | NanoViricides Inc. | $1.24 | +0.81% | $31.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier